



Imaxio acquires Trolovol® (D-penicillamine), an orphan drug indicated for a congenital metabolic disease

This acquisition strengthens Imaxio's pharmaceutical range, which now includes two products sold in France, and will finance the development of its vaccine candidates

Lyon, France – January 22, 2013 – Imaxio, a biopharmaceutical company specialising in vaccines and genomics, today announces the acquisition of Trolovol® (D-penicillamine), a drug for human usage indicated for an orphan disease affecting around 1,200 patients in France. This product previously belonged to D&A Pharma and the transaction was facilitated by CMC Consulting. The financial terms of the deal have not been disclosed.

This purchase will allow Imaxio to generate almost €500,000 of additional revenue in 2013, representing an increase of 20% in its turnover compared to 2012. This revenue will be re-invested in research and development activities relating to its proprietary technology for reengineering antigens, known as IMX313. This technology is used to significantly increase immunogenicity and thus the efficacy of vaccines in which it is used.

This acquisition also fits in with Imaxio's strategy of consolidating its pharmaceutical range. The company currently distributes Spirolept®, a human vaccine indicated for preventing a professional infectious disease, which became part of Imaxio's portfolio in 2009 following the acquisition of the company Axcell Biotechnologies. In 2012, sales of Spirolept® totalled almost €2 million and generated a turnover of €2.5 million.

"We are delighted to have finalised this transaction, which is a perfect fit for our external growth strategy," said Alexandre Le Vert, Managing Director of Imaxio. "With the revenue generated by the sales of Trolovol®, Imaxio will have the additional means necessary to advance in the clinical field, in particular with regard to its highly promising IMX313 technology for vaccines. Over the next three years, there are plans for Phase I/IIa clinical trials in indications for tuberculosis, influenza and Staphylococcus aureus infections."

In the medium term, Imaxio plans to acquire further new products and to licence its IMX313 immunogenic technology for new indications in human and animal healthcare.

About Imaxio SA

Imaxio SA is a biopharmaceutical company specialized in the areas of vaccines and genomics.

Using IMX313, its antigen re-engineering technology, Imaxio is developing, both individually and with its partners, recombinant vaccines with improved effectiveness for applications in both human and animal health. In France, Imaxio already markets Spirolept®, a human vaccine indicated for preventing a professional infectious disease, and Trolovol®, an orphan drug indicated for a congenital metabolic disease.

Imaxio's genomics division undertakes diagnostic and therapeutic research in the field of oncology and immunology, as well as providing services in the areas of human health, the agro-food business and the environment.

Imaxio was created through the merger between Diagnogene and Avidis, a spin-off from the Medical Research Council and Cambridge University in the UK. The company owns well-founded intellectual property and collaborates with numerous academic partners, including the Jenner Institute at Oxford University.

Imaxio SA is based in Lyon and at Saint Beauzire, near Clermont-Ferrand in France. It has 24 employees, ten of whom are engaged in R&D. In 2011 it delivered a turnover of EUR 2.4 million.

For more information, go to: <http://www.imaxio.com> and <http://www.genomics-imaxio.com>

About D&A

D&A Pharma is a French Pharmaceutical Company specialized in the development of innovative and patented treatments of addictions.

The Company has three key products under development. Its alcohol dependence treatment product (currently in Phase IIb/III trial) is a solid form of a liquid product which has been marketed for more than 15 years in Italy. This product has demonstrated strong efficacy with more than 400,000 alcohol dependent patients treated successfully. The Company is also developing a treatment for cocaine dependence (currently in Phase I trial), as well as a non-narcotic, non-addictive treatment for heroin dependence and moderate to severe pain.

D&A Pharma is organised around of team of experienced multidisciplinary scientists with a deep knowledge in the development of innovative formulations.

Created in 2006 by Patrice Debrégeas, former President and co-founder of Ethypharm, D&A Pharma has invested approximately €40m in its projects and in a state-of-the-art R&D site located in Houdan, near Paris, France. The company is headquartered in Paris.

For more information, go to: <http://www.da-pharma.fr> <<http://www.da-pharma.fr/>>

For more information on CMC Consulting : www.cmc-co.net

For further information, please contact:

Andrew Lloyd and Associates

Celine Gonzalez / Neil Hunter

celine@ala.com / neil@ala.com

Tel : +44 1273 675100
